
Please try another search
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
Name | Age | Since | Title |
---|---|---|---|
Leslie A. Leinwand | - | - | Member of Scientific Advisory Board |
Lee Sweeney | - | - | Member of Scientific Advisory Board |
Jonathan C. Fox | 68 | 2023 | Independent Director |
Arlene M. Morris | 74 | 2024 | Independent Director |
Alan J. Russell | 55 | 2017 | Co-Founder, Chief Scientific Officer & Director |
Peter A. Thompson | 65 | 2017 | Co-Founder & Independent Chairman |
Badreddin Edris | 38 | 2017 | Co-Founder & Independent Director |
Kevin Koch | 65 | 2017 | President, CEO & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review